生命科学资讯
生物技术与制药领域的最新动态
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Amgen advances toward lupus redemption while gastric cancer candidate struggles
美国卫生与公众服务部启动1亿美元抗病毒药物奖,旨在开发广谱疗法。
HHS launches $100M antiviral prize to develop broad-spectrum therapies
NIH风波成焦点,主任承认疫苗与自闭症无关。
NIH turmoil takes center stage as director acknowledges no vaccine-autism link
辉瑞CEO宣布,在完成六项早期项目削减及44亿美元减值后,管线优化已基本完成。
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
新兴生物科技公司Exxel计划通过1300万美元IPO,在FAAH抑制剂领域寻求突破。
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FDA暗示将采取定制化策略,以“审慎引导”CAR-T疗法用于自身免疫性疾病治疗。
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
查尔斯河将关闭细胞疗法CDMO基地,裁员20名员工。
Charles River to close cell therapy CDMO site, lay off 20 staffers
辉瑞每月投入100亿美元押注GLP-1药物,二期b阶段试验显示减肥效果具竞争力。
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
NMD罕见病试验失败,但借次要数据加速项目推进
NMD flunks rare disease trial but flexes secondary data to accelerate program
奎斯特推出多发性骨髓瘤残留病灶血液检测
Quest launches residual disease blood test for multiple myeloma
Mirum如何通过战略并购推动罕见病护理进步
How Mirum is Advancing Rare Disease Care Through Strategic M&A
诺和诺德CagriSema在3期糖尿病研究中优于司美格鲁肽。
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
葛兰素史克归还Wave遗传病RNA编辑技术权利
GSK gives back rights to Wave's genetic disease RNA editor
赛默飞世尔关闭富兰克林工厂,缩减马萨诸塞州员工规模。
Thermo Fisher trims Massachusetts headcount with Franklin site closure
葛兰素史克计划在美英两国裁员多达350名研发人员
GSK plans to lay off up to 350 R&D workers across US, UK
早期投资者Santé Ventures筹集3.3亿美元,布局生物科技、医疗科技与数字健康领域。
Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
罗氏重返RNA领域,以17亿美元收购赛诺基因项目。
Roche's return to RNA continues with $1.7B deal for Sanegene program
Optellum获英国国民医疗服务体系青睐,参与AI肺癌诊断项目。
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative